Publications

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse module

Wang F, Travins J, Lin Z, Si Y, Chen Y, Powe J, Murray S, Zhu D, Artin E, Gross S, Santiago S, Steadman M, Kernytsky A, Straley K, Lu C, Pop A, Struys EA, Jansen EE, Salomons GS, David MD, Quivoron C, Penard-Lacronique V, Regan KS, Liu W, Dang L, Yang H, Silverman L, Agresta S, Dorsch M, Biller S, Yen K, Cang Y, Su SM, Jin S.

J Inherit Metab Dis. 2016 Jul; 39(6): 807–820

PMID: 27469509

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065612/


The promises of quantitative systems pharmacology modelling for drug development

Knight-Schrijver VR, Chelliah V, Cucurull-Sanchez L, Le Novère N.

Comput Struct Biotechnol J. 2016 Sep;14:363-370

PMID: 27761201

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064996/

Abstract

Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output.


The role of chronic toxicology studies in revealing new toxicities

Galijatovic-Idrizbegovic A, Miller JE, Cornell WD, Butler JA, Wollenberg GK, Sistare FD, DeGeorge JJ.

Regul Toxicol Pharmacol. 2016 Oct; pii: S0273-2300(16)30299-9

PMID: 27769827

http://www.sciencedirect.com/science/article/pii/S0273230016302999

Abstract

Chronic (>3 months) preclinical toxicology studies are conducted to support the safe conduct of clinical trials exceeding 3 months in duration.